ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MSD’s Keytruda takes lead in squamous NSCLC trials
pharmatimes
June 06, 2018MSD’s Keytruda has shown a greater benefit than Roche’s Tecentriq in separate (and incomparable) clinical trials exploring the effectiveness of the anti-PD-1 therapies in treatment-naiive patients with squamous non-small cell lung cancer.
Pharma Sources Insight January 2025
